Link to article at PubMed

Milner Z and Akhondi H. StatPearls. StatPearls Publishing 2020 Jan– - Review.


Repaglinide is a drug used in the treatment of diabetes mellitus type 2. It belongs to a class of antihyperglycemic agents known as meglitinides, along with nateglinide. Meglitinides work to reduce blood glucose levels by stimulating endogenous insulin production. The present recommended starting dose is dependent on hemoglobin A1c levels, with those below 8% (64 mmol/mol) urged to start with 0.5mg pre-prandially, and those above 8% to start with 1 to 2mg.

PMID:32644731 | Bookshelf:NBK559305

Leave a Reply

Your email address will not be published.